Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician?s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01
Study Type: Treatment
Phase: III
NCTID: NCT06120491
Principal Investigator:
Elizabeth Wulff-Burchfield
A Phase III, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA IT PET/CT in Staging of Men with Newly Diagnosed Unfavorable Intermediate-risk, High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy with Pelvic Lymph Node Dissection
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Early Apical Release vs Classic Holmium Laser Enucleation of the Prostate: Randomized Controlled Trial Comparing Post-Operative Incontinence Rates and Surgical Outcomes
Study Type: Treatment
Phase: Feasibility/Pilot
NCTID: NCT04566588
Principal Investigator:
Kerri Thurmon
A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer COMPPARE
Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy ADT in High Risk Prostate Cancer with Initial Phase I NADIR Randomized Phase II Trial of Niraparib with Standard Combination Androgen Deprivation Therapy ADT and Radiotherapy in High Risk Prostate Cancer with Initial Phase I
A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events MACEs in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix GnRH Receptor Antagonist or Leuprolide GnRH Receptor Agonist
Prospective Validation of Prostate Biomarkers for Repeat Biopsy: The PRIORITY Study
Increasing the Dose of Survivorship Care Planning in Prostate Cancer Survivors Who Receive Androgen Deprivation Therapy
Study Type: Health Services
Phase: III
NCTID: NCT03860961
Principal Investigator:
Ronald Chen